robert l. coleman, md, facog, facs, on how veliparib factors into ovarian cancer treatment
Published 5 years ago • 50 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
3:19
robert l. coleman, md, facog, facs, on the role of hrd in the management of ovarian cancer
-
0:57
robert l. coleman, md, facog, facs, on takeaways from the ovarian plenary session at esmo '19
-
3:29
dr. coleman on advances made in ovarian cancer treatment
-
1:14
dr. coleman on rationale for using veliparib and chemotherapy in ovarian cancer
-
2:12
dr. coleman on the use of veliparib in advanced ovarian cancer
-
0:16
copy of dr. coleman on classifying patients with ovarian cancer
-
2:05
dr. coleman on the future of parp inhibitors in ovarian cancer
-
1:13
dr. coleman on implications of the velia trial in ovarian cancer
-
2:03
dr. coleman on results of the velia trial in ovarian cancer
-
1:55
rationale for chemotherapy plus veliparib in frontline treatment of ovarian cancers
-
1:14
dr. coleman on classifying patients with ovarian cancer
-
1:59
dr. coleman on next steps following ariel2 trial for ovarian cancer
-
1:14
dr. coleman on benefit of rucaparib in ovarian cancer
-
1:13
dr. coleman on recent advances and remaining questions in ovarian cancer
-
4:36
ovarian cancer: understanding treatment endpoints
-
1:35
dr. coleman on immunotherapy in ovarian cancer
-
33:15
ovarian cancer: standards of care and new opportunities - dr. robert coleman
-
2:35
dr. coleman on the results and key takeaways from gog0213
-
1:24
dr. coleman on the effect of age on the efficacy of rucaparib